The reductions in ambulatory and clinic BPs from baseline were highly significant and clinically important, showing greater dose‐related reductions for 80 mg vs 40 mg in this patient population.
← all excerpts
Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension.
1
—
—